Upadacitinib in Asian inflammatory bowel disease practice: encouraging real-world efficacy
Intestinal Research · 30.07.2026 · 24 (3) · 389-391
DOI: 10.5217/ir.2026.00200 ↗Kurz gefasst
Editorial in der Zeitschrift Intestinal Research, erschienen am 30.07.2026. Verfasst von Eun Soo Kim. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. dandy813@hanmail.net. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
treat population.Nearly all patients were biologic-experienced, and more than three-quarters had failed at least 2 advanced therapies.Such patients are frequently encountered in tertiary referral centers, where therapeutic sequencing has become increasingly complex.In this context, the observed response rates are clinically meaningful and reinforce the emerging perception that upadacitinib may retain efficacy even after multiple biologic failures.Second, the study emphasizes symptom-based patient-reported outcomes (PROs) rather than relying exclusively on conventional indices such as the Crohn' s Disease Activity Index or Mayo score.This approach reflects an important shift in modern IBD practice.While regulatory trials prioritize standardized composite endpoints, clinicians are often more concerned with rapid symptom relief, restoration of daily functioning, and steroid avoidance.From a practical standpoint, improvement in diarrhea frequency, abdominal pain, stool urgency, and rectal bleeding may better capture what truly matters to patients in routine care.Nevertheless, several issues warrant careful interpretation before these findings are generalized too broadly.Most importantly, the remarkably high remission rates should be interpreted cautiously.Real-world observational studies frequently report outcomes that differ substantially from randomized controlled trials because of heterogeneity in endpoint definitions, follow-up completeness, and treatment selection bias.In the present study, remission was assessed pri-
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. dandy813@hanmail.net.
Zitieren
APA
Kim, E. S. (2026). Upadacitinib in Asian inflammatory bowel disease practice: encouraging real-world efficacy. Intestinal Research, 24(3), 389-391. https://doi.org/10.5217/ir.2026.00200
Vancouver
Kim ES. Upadacitinib in Asian inflammatory bowel disease practice: encouraging real-world efficacy. Intestinal Research. 2026;24(3):389-391. doi:10.5217/ir.2026.00200
BibTeX
@article{Kim2026,
author = {Kim, Eun Soo},
title = {Upadacitinib in Asian inflammatory bowel disease practice: encouraging real-world efficacy},
journal = {Intestinal Research},
year = {2026},
volume = {24},
number = {3},
pages = {389--391},
doi = {10.5217/ir.2026.00200}
}
EUVIMED